Diagnosis & Disease Information

Pembrolizumab treatment resulted in high ORRs among patients with relapsed/refractory classic Hodgkin lymphoma regardless of previous therapy.

Survivors with a family history of colorectal, breast, and lung cancer were at a significantly higher risk of similar second cancers.

PD-1 blockade with nivolumab was active in patients with Hodgkin lymphoma who received allogeneic hematopoietic cell transplantation.

Adjusting treatment dose after 2 courses of first-line therapy based on a positive PET scan does not improve progression-free survival.

Treatment with anthracyclines increases the risk for developing heart failure by 3-fold independently of radiation dose among survivors of Hodgkin lymphoma.